Novartis files for Gleevec to treat four other cancers

04/10/2006 | Wall Street Journal, The

Novartis has applied in the U.S. and European Union to have its Gleevec, which is currently approved for treating types of leukemia and stomach cancers, also approved for use in fighting four other types of cancer. The filings are an indication of a movement under way in the drug industry in which the emphasis of cancer treatment is on genetic mutations now believed to be the cause of cancers, instead of specific body parts, The Wall Street Journal asserts.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Counsel, Regulatory (FDA)
CareFusion
San Diego , CA
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations